hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06349434, orgStudyIdInfo id: R-1215-23, briefTitle: The Utilization Effects of Powered Wearable Orthotics in Improving Upper Extremity Function and ADL in Persons With SCI, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-15, primaryCompletionDateStruct date: 2028-10-01, completionDateStruct date: 2028-10-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Kessler Foundation, class: OTHER, descriptionModule briefSummary: To evaluate the usefulness of an upper extremity assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury. The Department of Defense is supporting this study., conditionsModule conditions: SCI - Spinal Cord Injury, conditions: Upper Extremity Dysfunction, conditions: Upper Extremity Problem, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: Randomized Clinical Trial, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: MyoMo, interventions name: conventional therapy, outcomesModule primaryOutcomes measure: GRASSP, primaryOutcomes measure: Range of motion of hands and arms, primaryOutcomes measure: Muscle strength measurement, secondaryOutcomes measure: Spasticity measurement, secondaryOutcomes measure: Brain signals measurement, secondaryOutcomes measure: CUE-Q, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kessler Foundation, status: RECRUITING, city: West Orange, state: New Jersey, zip: 07052, country: United States, contacts name: Ghaith J Androwis, Ph.D., role: CONTACT, phone: 201-968-6110, email: gandrowis@kesslerfoundation.org, geoPoint lat: 40.79871, lon: -74.23904, hasResults: False
protocolSection identificationModule nctId: NCT06349421, orgStudyIdInfo id: 202401078RINE, briefTitle: Exploring the Impact of Fully Guided Implant Placement on Classifying Bone Quality Through Tactile Sensation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: National Taiwan University Hospital, class: OTHER, descriptionModule briefSummary: Bone quality stands as a crucial determinant impacting the success rate of dental implants, exerting influence on both implant primary stability and the efficacy of osseointegration. While radiographic images can partially reveal bone quality, experienced surgeons often rely on tactile sensation during bone drilling to assess it. Subsequently, based on the diagnosed bone quality, distinct implant designs and surgical protocols have been invented to enhance survival rates.Technological advancements now enable the preoperative design of implant placement through a comprehensive guide, merging CBCT DICOM files with digital oral scanning data. This "fully guided" approach enhances the precision, stability, and safety of implant placement surgery. However, the use of a fully guided surgical guide introduces an additional factor-the friction between the drill and guide-potentially impacting the surgeon's tactile feedback.This study aims to assess the difference in bone quality evaluation by tactile sensation between freehand drilling and drilling with a fully guided surgical guide, using test blocks of different bone density. The discussion will explore the pros and cons of employing a fully guided guide to optimize outcomes in implant treatment., conditionsModule conditions: Dentistry, conditions: Education, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 30, type: ESTIMATED, outcomesModule primaryOutcomes measure: VAS scale at the same density of sawbone, eligibilityModule sex: ALL, minimumAge: 24 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349408, orgStudyIdInfo id: CIBI3001A101, briefTitle: IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2026-05-30, completionDateStruct date: 2027-05-30, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Innovent Biologics (Suzhou) Co. Ltd., class: INDUSTRY, descriptionModule briefSummary: This is a Phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. It includes a Phase 1 section to identify Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of IBI3001, and a Phase 2 section to explore and confirm the efficacy, safety and tolerability of IBI3001 at its RP2D., conditionsModule conditions: Locally Advanced Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: IBI3001, outcomesModule primaryOutcomes measure: Number of subjects with adverse events, primaryOutcomes measure: Number of subjects with clinically significant changes in physical examination results, primaryOutcomes measure: Number of subjects with clinically significant changes in vital signs, primaryOutcomes measure: MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs), secondaryOutcomes measure: Plasma concentration (Cmax) of IBI3001, secondaryOutcomes measure: Area under the curve (AUC) of IBI3001, secondaryOutcomes measure: Time to maximum concentration (Tmax) of IBI3001, secondaryOutcomes measure: Clearance (CL) of IBI3001, secondaryOutcomes measure: Volume of distribution (V) of IBI3001, secondaryOutcomes measure: Half-life (T1/2) of IBI3001, secondaryOutcomes measure: Immunogenicity of IBI3001, secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Duration of response (DoR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Time to response (TTR), secondaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Overall survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wollongong Public, city: Wollongong, state: New South Wales, zip: 2500, country: Australia, contacts name: Daniel Brungs, role: CONTACT, email: Daniel.brungs@health.nsw.gov.au, geoPoint lat: -34.424, lon: 150.89345, hasResults: False
protocolSection identificationModule nctId: NCT06349395, orgStudyIdInfo id: NisantasiU, briefTitle: The Effect of Mindfulness-Based Stress Reduction Training Before Mastectomy on Postoperative Pain in Early Period, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2024-06-29, completionDateStruct date: 2024-07-29, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Istanbul Nisantasi University, class: OTHER, descriptionModule briefSummary: This research aims to investigate the effect of mindfulness-based stress reduction training given before mastectomy on postoperative early period pain and the fear of movement caused by pain. According to the World Health Organization, 18.1 million new cancer diagnoses are made each year, with breast cancer being the most common type among women, accounting for 24.2% of all cancers diagnosed. In Turkey, the incidence of breast cancer was determined as 22,345 in 2018. Breast cancer significantly affects women's quality and length of life. Surgical intervention is the most commonly chosen treatment method for cases of localized breast cancer. Pain and limited movement are among the most common problems encountered after surgery. Non-pharmacological methods have been shown to be effective in pain management, with the mindfulness-based stress reduction technique being one of these methods. This technique is described as an effective treatment for conditions such as pain, depression, and addiction, with high levels of mindfulness being associated with greater self-esteem, optimism, and empathy, whereas low levels of mindfulness are linked to depression, anxiety, chronic pain, and acute pain., conditionsModule conditions: Pain Management, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 2 parallel groups randomized controlled study, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: MBSR surgical nursing care, outcomesModule primaryOutcomes measure: Visual analog scale, primaryOutcomes measure: The Tampa Scale of Kinesiophobia, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul University - Cerrahpasa, status: RECRUITING, city: Istanbul, zip: 34160, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06349369, orgStudyIdInfo id: PG Thesis/2023-24/105, briefTitle: Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia, acronym: tDCS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2025-12-09, completionDateStruct date: 2026-04-09, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: All India Institute of Medical Sciences, Bhubaneswar, class: OTHER, descriptionModule briefSummary: The study is a randomized, double-blind, parallel-arm, sham-controlled trial that aims to compare the effects of transcranial direct current stimulation (tDCS) versus sham stimulation on inflammatory markers (IL-6 and TNF-alpha) and clinical outcomes (PANSS, AHRS, CGI-SCH, GAF) in patients with chronic schizophrenia over 10 days of treatment. The primary objective is to assess changes in IL-6 levels, while secondary objectives include evaluating changes in TNF-alpha, symptom scales, and adverse events. The study will be conducted at the psychiatry department of AIIMS Bhubaneswar, with 60 patients aged 18-60 years with moderate-to-severe schizophrenia symptoms randomized to receive either active tDCS (cathode over left temporo-parietal junction, anode over left dorsolateral prefrontal cortex) or sham stimulation. The researchers hope to elucidate the potential immunomodulatory effects of tDCS and its impact on symptoms in chronic schizophrenia, which may lead to more targeted, multifaceted interventions to improve patient outcomes., conditionsModule conditions: Chronic Schizophrenia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: transcranial direct current stimulation, outcomesModule primaryOutcomes measure: Change in the IL-6 levels, secondaryOutcomes measure: Change in the TNF alpha levels., secondaryOutcomes measure: Change in the Positive and Negative syndrome Scale, secondaryOutcomes measure: Change in the Auditory hallucination rating scale, secondaryOutcomes measure: Change in the Clinical global impression- Schizophrenia scale, secondaryOutcomes measure: Change in the Global Assessment of Functioning scale, secondaryOutcomes measure: To compare the adverse events reported in both control and intervention groups., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: AIIMS Bhubaneswar, status: RECRUITING, city: Bhubaneswar, state: Odisha, zip: 751019, country: India, contacts name: Ashutosh Biswas, role: CONTACT, geoPoint lat: 20.27241, lon: 85.83385, hasResults: False
protocolSection identificationModule nctId: NCT06349343, orgStudyIdInfo id: UHCT230949, briefTitle: CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Wuhan Union Hospital, China, class: OTHER, descriptionModule briefSummary: The purpose of the study is to explore the safety and efficacy of cluster of differentiation 19 (CD19)/B cell maturation antigen (BCMA) human leukocyte antigen (HLA)-independent T cell receptor (TCR) -T therapy in refractory/moderate-to-severe systemic lupus erythematosus(SLE)., conditionsModule conditions: Systemic Lupus Erythematosus, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: CD19/BCMA Hi-TCR-T cell therapy, outcomesModule primaryOutcomes measure: Safety and tolerability, secondaryOutcomes measure: Proportion of subjects with SRI-4 response, secondaryOutcomes measure: Changes in the Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score from baseline, secondaryOutcomes measure: Changes in the BILAG-2004 score from baseline, secondaryOutcomes measure: Changes in the Physician Global Assessment (PGA) score from baseline, secondaryOutcomes measure: Pharmacokinetics (PK), secondaryOutcomes measure: Pharmacodynamics (PD), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349317, orgStudyIdInfo id: 2024-005, briefTitle: Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Yongyi Zeng, class: OTHER, descriptionModule briefSummary: This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of resectable hepatocellular carcinoma with portal vein tumor thrombus., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 33, type: ESTIMATED, armsInterventionsModule interventions name: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib, outcomesModule primaryOutcomes measure: 1-year Event-Free Survival (EFS) rate, secondaryOutcomes measure: Event-Free Survival (EFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Disease-Free Survival (DFS), secondaryOutcomes measure: R0 resection rate, secondaryOutcomes measure: Overall Objective Response of primary liver tumor and PVTT, otherOutcomes measure: Surgical safety, otherOutcomes measure: Safety of radiotherapy, camrelizumab and apatinib treatment, otherOutcomes measure: Exploratory Endpoints, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349304, orgStudyIdInfo id: S25, briefTitle: Impact of Grape Powder Consumption on Eye Health and Glycemic Status in Singapore Older Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-08-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: National University of Singapore, class: OTHER, collaborators name: California Table Grape Commission, descriptionModule briefSummary: The purpose of this study is to understand the impacts of regular consumption of freeze-dried table grape powder on eye health and regulation of advanced glycation end products in Singapore older adults. The investigators hypothesize that regular consumption of freeze-dried table grape powder will promote improvements in eye health and lower levels of advanced glycation end products when compared to the placebo group., conditionsModule conditions: Macula; Degeneration, conditions: Aging, conditions: Advanced Glycation End Products, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Freeze-dried table grape powder, interventions name: Placebo grape powder, outcomesModule primaryOutcomes measure: Macular pigment optical density, primaryOutcomes measure: Visual acuity, primaryOutcomes measure: Photostress recovery time, primaryOutcomes measure: Visual function questionnaire 25, primaryOutcomes measure: Skin advanced glycation end products levels, primaryOutcomes measure: Dietary advanced glycation end products level, primaryOutcomes measure: Blood advanced glycation end products levels, primaryOutcomes measure: Contrast sensitivity, secondaryOutcomes measure: Concentration of tumour necrosis factor-α, secondaryOutcomes measure: Concentration of interleukin-6, secondaryOutcomes measure: Concentration of high-sensitivity C-reactive protein, secondaryOutcomes measure: Concentration of fasting blood glucose, secondaryOutcomes measure: Concentration of malondialdehyde, secondaryOutcomes measure: Concentration of 8-isoprostaglandin-F2α, secondaryOutcomes measure: Skin carotenoid status, secondaryOutcomes measure: Concentration of insulin, secondaryOutcomes measure: Percentage of glycated hemoglobin, otherOutcomes measure: Measurement of height, otherOutcomes measure: Measurement of blood pressure, otherOutcomes measure: Measurement of weight, otherOutcomes measure: Measurement of waist circumference, eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349291, orgStudyIdInfo id: 0074-24-MMC, briefTitle: Venous Thrombosis After Removal of Central Venous Catheter, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-08-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Meir Medical Center, class: OTHER, descriptionModule briefSummary: Insertion of intravenous catheter is a very common operation in patients in the general intensive care unit. These catheters are used for a variety of purposes - administration of inotropics/pressors, intravenous nutrition, concentrated electrolytes and performing dialysis.There are several known complications of central venous catheter insertion, such as thrombosis and pulmonary embolism. In a literature review, there are no clear data regarding the rate of intravenous thrombosis in patients after removal of a central venous catheter. These findings are often discovered randomly, when the patient undergoes imaging for a different indication. There is no recommendation for an active search for intravenous thrombi at the catheter insertion sites in these patients, and it is not entirely clear whether it is mandatory to administer anticoagulant treatment in these patients if thrombi are randomly discovered at the catheter insertion sites.In this study, we aim to check the proportion of patients who developed thrombosis at the central catheter insertion sites after its removal, to check whether there are catheter insertion sites that are at a higher risk of developing thrombosis than other sites, and to check whether there are predictive characteristics for the development of this type of thrombosis., conditionsModule conditions: Thrombosis, Venous, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Detection of venous thrombosis via US, outcomesModule primaryOutcomes measure: Rate of DVT after removal of central venous catheter, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Meir Medical Center, city: Kfar Saba, country: Israel, geoPoint lat: 32.175, lon: 34.90694, hasResults: False